Published in CNS Spectr on January 01, 2007
Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10. BMC Neurosci (2009) 1.00
Consumption of pasteurized human lysozyme transgenic goats' milk alters serum metabolite profile in young pigs. Transgenic Res (2009) 0.93
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol (2010) 0.93
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med (2010) 0.88
A Drosophila model for primary coenzyme Q deficiency and dietary rescue in the developing nervous system. Dis Model Mech (2010) 0.82
Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. Int J Mol Sci (2012) 0.80
Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. J Alzheimers Dis (2012) 0.78
Oral antioxidant therapy for juvenile rats with kaolin-induced hydrocephalus. Fluids Barriers CNS (2014) 0.75
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA (2002) 6.72
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med (2007) 4.49
The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology (2005) 4.44
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol (2012) 3.19
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimers Dement (2006) 2.51
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2008) 2.32
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
Reducing suicidal ideation in depressed older primary care patients. J Am Geriatr Soc (2006) 2.11
Head injury in early adulthood and the lifetime risk of depression. Arch Gen Psychiatry (2002) 1.97
Psychiatric disease in the twenty-first century: The case for subcortical ischemic depression. Biol Psychiatry (2006) 1.94
Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy (2003) 1.93
Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry (2006) 1.92
Depression treatment preferences in older primary care patients. Gerontologist (2006) 1.92
Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology (2003) 1.87
Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging. Radiology (2007) 1.77
Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry (2002) 1.75
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc (2010) 1.73
Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression. Biol Psychiatry (2006) 1.73
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry (2010) 1.72
Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol (2011) 1.63
Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc (2010) 1.60
Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry (2004) 1.55
Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics (2005) 1.52
Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc (2004) 1.49
Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology (2004) 1.48
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry (2005) 1.47
Vascular risk factors and cognitive decline among elderly male twins. Neurology (2006) 1.47
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry (2004) 1.46
White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry (2003) 1.46
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2004) 1.46
Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr (2006) 1.45
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep) (2007) 1.42
Depressive state- and disease-related alterations in neural responses to affective and executive challenges in geriatric depression. Am J Psychiatry (2008) 1.42
Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders. Front Psychiatry (2013) 1.40
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry (2003) 1.40
Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry (2005) 1.39
Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res (2005) 1.39
Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology (2006) 1.37
Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol (2003) 1.34
Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy (2004) 1.33
Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy (2003) 1.32
Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement (2008) 1.32
Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry (2002) 1.31
Aging, gender, and the elderly adult brain: an examination of analytical strategies. Neurobiol Aging (2006) 1.30
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord (2013) 1.28
Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS One (2007) 1.28
Olanzapine-associated diabetes mellitus. Pharmacotherapy (2002) 1.24
A brief review of the pathophysiology, associated pain, and psychosocial issues in sickle cell disease. Int J Behav Med (2005) 1.24
Parental substance abuse, reports of chronic pain and coping in adult patients with sickle cell disease. J Natl Med Assoc (2006) 1.23
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. Psychosom Med (2007) 1.22
Profiles of depressive symptoms in older adults diagnosed with major depression: latent cluster analysis. Am J Geriatr Psychiatry (2009) 1.21
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy (2006) 1.20
Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry. Twin Res Hum Genet (2006) 1.19
A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry (2007) 1.19
The vascular depression subtype: evidence of internal validity. Biol Psychiatry (2008) 1.19
Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry (2008) 1.18
The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci (2003) 1.18
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med (2007) 1.17
Calcium and vitamin D intakes may be positively associated with brain lesions in depressed and nondepressed elders. Nutr Res (2008) 1.16
Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc (2011) 1.15
Neurocognitive correlates of response to treatment in late-life depression. Am J Geriatr Psychiatry (2008) 1.15
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry (2006) 1.15
A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc (2013) 1.14
Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc (2003) 1.14
National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med (2015) 1.12
Localization of age-associated white matter hyperintensities in late-life depression. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.11
Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study. Am J Geriatr Psychiatry (2006) 1.10
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A (2003) 1.10
Psychosocial and clinical predictors of unipolar depression outcome in older adults. Int J Geriatr Psychiatry (2002) 1.10
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs (2010) 1.10
Marked increase in Alzheimer's disease identified in medicare claims records between 1991 and 1999. J Gerontol A Biol Sci Med Sci (2004) 1.09
Contribution of depression to cognitive impairment and dementia in older adults. Neurologist (2007) 1.09
Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med (2010) 1.09
Frontal white matter anisotropy and antidepressant remission in late-life depression. PLoS One (2008) 1.09
Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites. Alzheimers Dement (2009) 1.08
Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. Psychol Med (2007) 1.07
Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. Am J Geriatr Psychiatry (2005) 1.06
Gender differences in the association between religious involvement and depression: the Cache County (Utah) study. J Gerontol B Psychol Sci Soc Sci (2006) 1.06
Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging (2006) 1.05
Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry (2008) 1.05
Reduction of dorsolateral prefrontal cortex gray matter in late-life depression. Psychiatry Res (2011) 1.05
The impact of religious practice and religious coping on geriatric depression. Int J Geriatr Psychiatry (2003) 1.05
Smaller orbital frontal cortex volumes associated with functional disability in depressed elders. Biol Psychiatry (2003) 1.05
The brain-derived neurotrophic factor VAL66MET polymorphism and cerebral white matter hyperintensities in late-life depression. Am J Geriatr Psychiatry (2008) 1.04
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ (2013) 1.03